Imad Shawa Selected Research

Disease Progression

12/2021	A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2.
10/2021	Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Imad Shawa Research Topics

Disease

6	COVID-19 01/2022 - 01/2021
2	Disease Progression 12/2021 - 10/2021
1	Pneumonia (Pneumonitis) 01/2022
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/2022
1	Respiratory Insufficiency (Respiratory Failure) 01/2022
1	Sepsis (Septicemia) 01/2022
1	Severe Acute Respiratory Syndrome 12/2021
1	Infections 10/2021
1	Immediate Hypersensitivity 01/2021

Drug/Important Bio-Agent (IBA)

4	bamlanivimabIBA 01/2022 - 01/2021
4	bamlanivimab and etesevimab drug combinationIBA 01/2022 - 01/2021
3	Monoclonal AntibodiesIBA 01/2022 - 10/2021
3	etesevimabIBA 01/2022 - 01/2021
2	VaccinesIBA 12/2021 - 10/2021
2	Neutralizing AntibodiesIBA 01/2021 - 01/2021
1	zansecimabIBA 01/2022
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2022
1	Angiopoietin-2IBA 01/2022

Therapy/Procedure

2	Intravenous Infusions 10/2021 - 01/2021
1	Mechanical Ventilators (Ventilator) 01/2022
1	Artificial Respiration (Mechanical Ventilation) 01/2022
1	Therapeutics 01/2021